Traws Pharma (TRAW) Competitors $2.86 +0.19 (+7.12%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$2.78 -0.08 (-2.80%) As of 10/17/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRAW vs. IMMX, ASRT, UNCY, VXRT, RPTX, XBIT, LITS, EQ, OKYO, and COEPShould you be buying Traws Pharma stock or one of its competitors? The main competitors of Traws Pharma include Immix Biopharma (IMMX), Assertio (ASRT), Unicycive Therapeutics (UNCY), Vaxart (VXRT), Repare Therapeutics (RPTX), XBiotech (XBIT), Lite Strategy (LITS), Equillium (EQ), OKYO Pharma (OKYO), and Coeptis Therapeutics (COEP). These companies are all part of the "pharmaceutical products" industry. Traws Pharma vs. Its Competitors Immix Biopharma Assertio Unicycive Therapeutics Vaxart Repare Therapeutics XBiotech Lite Strategy Equillium OKYO Pharma Coeptis Therapeutics Immix Biopharma (NASDAQ:IMMX) and Traws Pharma (NASDAQ:TRAW) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability. Does the media prefer IMMX or TRAW? In the previous week, Traws Pharma had 3 more articles in the media than Immix Biopharma. MarketBeat recorded 5 mentions for Traws Pharma and 2 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 0.99 beat Traws Pharma's score of 0.33 indicating that Immix Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immix Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Traws Pharma 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals believe in IMMX or TRAW? 11.3% of Immix Biopharma shares are owned by institutional investors. Comparatively, 8.0% of Traws Pharma shares are owned by institutional investors. 55.4% of Immix Biopharma shares are owned by company insiders. Comparatively, 14.0% of Traws Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts rate IMMX or TRAW? Immix Biopharma currently has a consensus price target of $8.00, indicating a potential upside of 178.75%. Given Immix Biopharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Immix Biopharma is more favorable than Traws Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immix Biopharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Traws Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has higher valuation & earnings, IMMX or TRAW? Immix Biopharma has higher earnings, but lower revenue than Traws Pharma. Immix Biopharma is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmix BiopharmaN/AN/A-$21.61M-$0.77-3.73Traws Pharma$230K88.66-$166.52M$88.830.03 Which has more volatility & risk, IMMX or TRAW? Immix Biopharma has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500. Comparatively, Traws Pharma has a beta of 1.69, meaning that its share price is 69% more volatile than the S&P 500. Is IMMX or TRAW more profitable? Traws Pharma has a net margin of 3,028.25% compared to Immix Biopharma's net margin of 0.00%. Immix Biopharma's return on equity of -205.35% beat Traws Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Immix BiopharmaN/A -205.35% -110.63% Traws Pharma 3,028.25%-1,812.48%512.72% SummaryImmix Biopharma beats Traws Pharma on 8 of the 15 factors compared between the two stocks. Get Traws Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TRAW and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRAW vs. The Competition Export to ExcelMetricTraws PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.03M$2.64B$6.10B$10.50BDividend YieldN/A57.79%5.73%4.81%P/E Ratio0.0322.9984.5227.09Price / Sales88.66709.05586.66210.72Price / CashN/A168.7137.1661.22Price / Book-0.335.3212.246.52Net Income-$166.52M$33.06M$3.32B$276.75M7 Day Performance-4.98%2.44%1.25%2.00%1 Month Performance38.83%6.46%6.28%2.26%1 Year Performance-41.15%-5.42%59.92%35.58% Traws Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRAWTraws Pharma0.842 of 5 stars$2.86+7.1%N/A-39.1%$19.03M$230K0.0317IMMXImmix Biopharma3.3345 of 5 stars$2.48-0.8%$8.00+222.6%+69.8%$82.59MN/A-3.229Gap DownASRTAssertio2.8539 of 5 stars$0.86+2.5%$2.38+175.2%-31.0%$81.04M$124.96M-1.9220Positive NewsUNCYUnicycive Therapeutics3.0951 of 5 stars$4.56+1.6%$57.00+1,150.0%+3.5%$79.30MN/A-1.119Gap UpVXRTVaxart1.9175 of 5 stars$0.34+1.3%$2.00+482.2%-55.5%$78.64M$47.40M-1.27120RPTXRepare Therapeutics2.7575 of 5 stars$1.87+2.7%$4.50+140.6%-45.4%$78.19M$53.48M-0.72180High Trading VolumeXBITXBiotech1.8383 of 5 stars$2.51-2.0%N/A-67.0%$78.05M$4.01M-2.73100Short Interest ↓LITSLite StrategyN/A$2.19+1.9%N/AN/A$76.66M$65.30M-0.46100News CoverageEQEquillium0.4428 of 5 stars$1.24-3.1%$1.00-19.4%+35.2%$76.16M$41.10M-2.2140Negative NewsShort Interest ↑OKYOOKYO Pharma2.4619 of 5 stars$1.95-2.5%$7.00+259.0%+117.5%$75.22MN/A0.007Gap DownCOEPCoeptis Therapeutics0.6938 of 5 stars$15.53-0.1%N/A+286.4%$74.96M$263.56K-2.682Short Interest ↑ Related Companies and Tools Related Companies Immix Biopharma Competitors Assertio Competitors Unicycive Therapeutics Competitors Vaxart Competitors Repare Therapeutics Competitors XBiotech Competitors Lite Strategy Competitors Equillium Competitors OKYO Pharma Competitors Coeptis Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRAW) was last updated on 10/18/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Traws Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Traws Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TRAW Stock Alerts